Sound Blade Medical Appoints Neil Barman, M.D. as Chief Executive Officer
HALIFAX, NS, July 31, 2025 /CNW/ -- Sound Blade Medical, Inc., a leader in handheld histotripsy therapy, today announced the appointment of Neil Barman, M.D. as Chief Executive Officer. Dr. Barman, a physician-executive with more than two decades of medical technology leadership experience, previously served as the company's Chief Operating Officer and will now guide Sound Blade through its next phase of clinical development.
"Neil brings an exceptional combination of leadership, clinical insight, and MedTech expertise," said Tony Natale, M.D., Executive Chairman of Sound Blade Medical. "As we advance our technology toward clinical application, his proven ability to drive innovation and execute strategic initiatives makes him the ideal leader for this next chapter."
Dr. Barman brings extensive experience in the medical technology sector. Prior to joining Sound Blade Medical, Dr. Barman served as Chief Scientific Officer at ReCor Medical, where he played a pivotal role in securing the first FDA approval for ultrasound renal denervation therapy. He also co-founded May Health, which develops novel treatments for PCOS-related infertility, and has held senior leadership roles at multiple MedTech companies that were later acquired by industry leaders including Medtronic and Stryker.
The company also announced that Jeremy Brown, Ph.D., founder and inventor, will continue to serve as Chief Technical Officer going forward.
"Jeremy's groundbreaking work in handheld histotripsy established the scientific foundation of Sound Blade," said Dr. Barman. "His leadership has been instrumental in transforming the company from an innovative concept to a platform positioned for meaningful clinical impact. We are fortunate to continue benefiting from his deep technical expertise in his role as CTO."
Dr. Brown founded Sound Blade with a vision of developing a truly non-invasive therapeutic platform using focused ultrasound to replace traditional surgical approaches across multiple medical conditions. Under his leadership, the company advanced its proprietary histotripsy technology into a compact, handheld form – an achievement that positions Sound Blade at the forefront of non-invasive surgical innovation.
"I'm incredibly proud of what our team has accomplished since founding Sound Blade," said Dr. Brown. "The technology we've developed has the potential to transform patient care across numerous therapeutic areas. I look forward to continuing our scientific journey as CTO and working closely with Neil as he leads our next phase of growth and clinical development."
About Sound Blade Medical
Sound Blade Medical is developing breakthrough handheld histotripsy technology that harnesses focused ultrasound to mechanically liquify targeted tissue without thermal damage, allowing for truly non-invasive surgical solutions. The company's innovative platform aims to transform patient care by replacing traditional surgical approaches across multiple medical conditions. The Sound Blade system is limited to investigational use and is not available for sale. For more information, visit www.soundblademedical.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Calgary Herald
4 days ago
- Calgary Herald
How fear, racism and smallpox fuelled an attack on Calgary's first Chinatown
Article content The narrative that the outbreak of smallpox was the fault of Chinese migrants from Vancouver and Victoria was reported in the Calgary Herald in the weeks before the event. Article content 'If the Chinese now at the quarantine are sent back into town there will be trouble,' said a July 19 editorial. Article content Though initial coverage of the riot in an article titled Hunting Chinamen condemned the violence — commending the town of Calgary's 'orderly, law-respecting spirit' — later comments in the Herald would suggest methods to root out the 'obnoxious element' while respecting their right to personal liberty and safety. Article content 'We may decide among ourselves that these may become nests of disease, and we may abstain from sending washing to them,' an Aug. 5 article said of the Chinese laundries on Stephen Avenue. Article content Article content Tony Wong, the former president of the Chinese Cultural Centre in Calgary, says the riot still exists in the cultural memory of Calgary's Chinese population, though only among historically minded members of the community. Article content Article content 'When the culture centre first opened in 1992, every year we received over 400 school groups, and I often would conduct tours,' he says. Article content But as the education system moved away from Chinese history and culture, he notes that the knowledge of the Calgary Chinese community's history declined. Article content He says that although the outright prejudice against Chinese people has waned, the otherness — or quality of being different — experienced by the Chinese population is alive and well. Article content During the COVID-19 pandemic, subtle discrimination emerged in new ways. Angie Wong says fears about the virus's origin echoed historical stereotypes of Chinese people as disease-carrying — the same narratives that fuelled the smallpox riot in 1892. Article content The Calgary Police Service publicly noted an increase in hate‑motivated incidents during the pandemic directed at Asian Canadians in the city. Unlike in 1892, where city officials largely dismissed violence, local authorities in 2020 and 2021 explicitly monitored and investigated COVID‑related anti‑Asian incidents, including vandalism and verbal harassment. Article content Article content For many in the community, it was a painful reminder: Even a century later, prejudice can resurface, especially in times of fear. Article content Tony Wong says it will take effort to connect Calgarians with the Chinese community, but it can be done. Article content 'I worked in Sun Life Plaza, right across the street from Chinatown, for 20 years, and some of my colleagues have never set foot in Chinatown,' he says. 'It's something they don't understand. So, I'm not saying that these colleagues of mine, they have prejudice, but they have some mental block.'
Globe and Mail
5 days ago
- Globe and Mail
37 Capital Settles Debt
Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - 37 Capital Inc. (CSE: JJJ) ("37 Capital" or the "Company") wishes to announce that further to the Company's news releases dated July 23 & 24, 2025, the Company has issued to a related party (the "Creditor") 1,330,000 common shares at a deemed price of $0.09 per share in settlement of debt totaling the amount of $119,700. All securities that have been issued are subject to a hold period expiring December 2, 2025. Related Party Transaction The Creditor is considered to be a related party transaction within the meaning of Multilateral Instrument 61-101- Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The related party transaction is exempt from minority approval, information circular and formal valuation requirements pursuant to the exemptions contained in Sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the securities being issued nor the debt settlement amount exceed 25% of the Company's market capitalization. For more information on the Company, you may contact us at (604) 681-0204, or visit the Company's website at or the CSE's website by using the following direct link: On Behalf of the Board of 37 Capital Inc., "Jake H. Kalpakian" ________________________ Jake H. Kalpakian, President and CEO The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. Trading in the securities of the Company should be considered speculative. Certain statements contained herein are "forward-looking". Forward-looking statements may include, among others, statements regarding future plans, projected or proposed financings, costs, objectives, economic or technical performance, or the assumptions underlying any of the foregoing. In this News Release, words such as "may", "would", "could", "will", "likely", "enable", "feel", "seek", "project", "predict", "potential", "should", "might", "objective", "believe", "expect", "propose", "anticipate", "intend", "plan", "plans" "estimate", and similar words are used to identify forward-looking statements. Forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those expressed or implied. Although management believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, projections and estimations, there can be no assurance that these assumptions, projections or estimations are accurate. Readers, shareholders and investors are therefore cautioned not to place reliance on any forward-looking statements as the plans, assumptions, intentions or expectations upon which they are based might not occur.
Globe and Mail
6 days ago
- Globe and Mail
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
Johnson & Johnson JNJ announced strong second-quarter results earlier this month. The drug and medical device giant beat estimates for both earnings and sales. Despite the loss of exclusivity ('LOE') of its blockbuster drug, Stelara, its Innovative Medicine unit once again outperformed expectations, with sales of all key drugs Darzalex, Erleada and Tremfya beating estimates. The new drugs also contributed significantly to sales. Importantly, its MedTech sales improved from first-quarter levels, driven by strong momentum in Cardiovascular, Surgery and Vision segments despite continued headwinds in China. But what caught investor attention is the fact that J&J raised its sales expectations for 2025 by around $2.0 billion at the mid-point to reflect a strong operational performance in the first half, coupled with currency tailwinds. The sales guidance was raised from a range of $91.0 billion-$91.8 billion to $93.2 billion-$93.4 billion. The sales range indicates growth in the range of 5.1%-5.6% versus the prior expectation of 2.6%-3.6%. The adjusted earnings per share guidance was raised from a range of $10.50-$10.70 to $10.80-$10.90, driven by top-line strength, the favorable impact of foreign currency and lowered tariff impact. J&J halved its expectations for tariff-related costs this year from $400 million to $200 million. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first. Newly launched products should drive better growth in the Innovative Medicine segment in the second half despite the impact of Stelara LOE and Medicare Part D redesign. The growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato and Erleada as well as new drugs like Carvykti, Tecvayli and Talvey and new indications, including Tremfya in inflammatory bowel disease indications and Rybrevant in non-small cell lung cancer. In the MedTech segment, the increased adoption of newly launched products in Cardiovascular, Surgery and Vision is likely to drive growth. However, China will continue to be a headwind in 2025. Sales are expected to be higher in the second half than the first half as the business moves past tougher first-half comps and new products gain momentum throughout 2025. We believe that J&J should be able to maintain the strong momentum of the first half in the second half. In fact, J&J expects growth to accelerate from 2026. ABBV & BMY Also Raise Guidance Other drugmakers that also raised their financial outlook for the year, along with their second-quarter results, are AbbVie ABBV and Bristol-Myers BMY. ABBV raised its full-year 2025 EPS guidance to $11.88-$12.08, up from its prior $11.67-$11.87 range.' Bristol-Myers raised its annual revenue guidance to $46.5-$47.5 billion from $45.8-$46.8 billion. BMY, however, cut its EPS outlook due to IPRD charges related to its recent deal with BioNTech BNTX for the global co-development and co-commercialization of BNTX's investigational bispecific antibody BNT327 across numerous solid tumor types. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 17.6% in the year-to-date period against a 3.3% decrease of the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company's shares currently trade at 15.0 forward earnings, slightly higher than 14.29 for the industry. The stock is, however, trading below its five-year mean of 15.68. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has risen from $10.62 per share to $10.86 over the past 30 days, while that for 2026 has risen from $11.0 to $11.36 over the same timeframe. Image Source: Zacks Investment Research J&J has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
